Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole in Basal Cell Carcinoma
NCT01108094Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 2010
- Primary completion
- Mar 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of itraconazole in basal cell carcinoma (BCC) (3 arms), sponsored by Stanford University. Primary endpoint: Ki67 Tumor Proliferation Biomarker at 1 month. Started Apr 2010; status: completed.
02
Drugs
itraconazole
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT01108094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01108094.